CMMB Chemomab Therapeutics Ltd.
$2.82 +3.30%
Updated
Healthcare · Pharmaceutical Preparations
Chemomab Therapeutics Ltd. (CMMB) is a healthcare company in the Pharmaceutical Preparations industry. Shares last traded at $2.82, 23.6% below their 52-week high. Over the past year the stock is down 17.3%.
Market Cap
—
Shares Out
—
EPS (TTM)
$0.20
P/E Ratio
14.31
P/S Ratio
—
P/B Ratio
—
Dividend / Share
—
Dividend Yield
—
52-Week High
$3.69
52-Week Low
$1.37
Volume
3,484
Avg Vol (3m)
4,175.349
Performance
1W
+5.22%
1M
+61.14%
3M
+67.86%
6M
+81.94%
YTD
+55.80%
1Y
-17.30%
Chart
Full chart →Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.
Technicals
RSI (14)
83.39
SMA (50)
$1.90
SMA (200)
$1.86
Price vs SMA50
+48.48%
Price vs SMA200
+51.45%
ATR (14)
$0.15
Financials
Revenue
—
Net Income
$-9M
Gross Margin
—
Operating Margin
—
Net Margin
—
Return on Equity
-72.9%
Return on Assets
-65.1%
Current Ratio
9.08
Debt / Equity
0.12
Revenue Growth (YoY)
—
Latest reported annual period ending 2025-06-30 · SEC EDGAR/XBRL.
Recent earnings
| Period | EPS (diluted) | Reported |
|---|---|---|
| Q1 2023 | $0.04 | 2023-05-11 |
| FY 2022 | $0.12 | 2023-03-20 |
| Q3 2022 | $0.09 | 2022-11-10 |
| Q2 2022 | $0.05 | 2022-08-12 |
| Q1 2023 | $0.02 | 2023-05-11 |
| FY 2022 | $0.06 | 2023-03-20 |
Pharmaceutical Preparations peers
CMMB vs 14 industry peers (Pharmaceutical Preparations), by market cap. Updated
1–14 of 14
| LLY | Lilly (Eli) | $1.09T | 40.86 | 13.70 | 33.5% | -0.02% |
| JNJ | Johnson & Johnson | $670.6B | 31.88 | 6.85 | 21.5% | +1.04% |
| ONC | Beone Medicines Ltd. | $535.9B | 817.25 | 87.43 | 10.7% | +0.23% |
| ABBV | AbbVie | $459.8B | 72.87 | 7.14 | 9.8% | -0.57% |
| MRK | Merck | $375.8B | 118.44 | 5.65 | 4.8% | +0.44% |
| ABT | Abbott Laboratories | $189.5B | 30.20 | 4.20 | 13.9% | -1.50% |
| PFE | Pfizer | $164.2B | 37.91 | 2.58 | 6.8% | -0.76% |
| VRTX | Vertex Pharmaceuticals | $141.5B | 32.11 | 11.24 | 35.0% | +0.24% |
| BMY | Bristol Myers Squibb | $139.1B | 14.98 | 2.83 | 18.9% | +0.62% |
| REGN | Regeneron Pharmaceuticals | $87.2B | 20.15 | 5.61 | 27.9% | -1.02% |
| TEVA | Teva Pharmaceutical Industries Ltd | $42.6B | 60.41 | 2.46 | 4.1% | -2.32% |
| ALNY | Alnylam Pharmaceuticals | $35.4B | 43.77 | 9.52 | 21.8% | -1.10% |
| ZTS | Zoetis | $31.5B | 12.05 | 3.31 | 27.5% | +0.16% |
| RPRX | Royalty Pharma Plc | $28.2B | 34.56 | 11.11 | 32.1% | +1.24% |
Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.